about
A Perspective of Immunotherapy for Prostate CancerPrognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical reviewFunctional magnetic resonance imaging in prostate cancer.Classification of prostatic diseases by means of multivariate analysis on in vivo proton MRSI and DCE-MRI data.Multidisciplinary management of Prostate Cancer: how and why.Thulium laser supported nephron sparing surgery for renal cell carcinoma.[Combined dutasteride and tamsulosin].Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.Histopathological aspects associated with the diagnosis of benign prostatic hyperplasia: clinical implications.Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable?Antiandrogen monotherapy: recommendations for the treatment of prostate cancer.Intermittent androgen deprivation in prostate cancer cases with biochemical progression after radical prostatectomy: Are we ready to treat?Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma.New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.The IGF axis in prostate cancer.Inflammation and chronic prostatic diseases: evidence for a link?Prostate growth and inflammation.New anti-angiogenic targeted therapy in advanced renal cell carcinoma (RCC): current status and future prospects.Modern role of magnetic resonance and spectroscopy in the imaging of prostate cancer.Randomized trial comparing an anterograde versus a retrograde approach to open radical prostatectomy: results in terms of positive margin rate.Update on screening in prostate cancer based on recent clinical trials.The emerging role of targeted therapy in renal cell carcinoma (RCC): is it time for a neoadjuvant or an adjuvant approach?Comparative analysis of multiparametric magnetic resonance and PET-CT in the management of local recurrence after radical prostatectomy for prostate cancer.Long term patient satisfaction and quality of life with AMS700CX inflatable penile prosthesis.Deregulation of MicroRNAs mediated control of carnitine cycle in prostate cancer: molecular basis and pathophysiological consequences.A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer.Effect of Serenoa repens (Permixon®) on the expression of inflammation-related genes: analysis in primary cell cultures of human prostate carcinoma.GNRH-agonist or antagonist in the treatment of prostate cancer: a comparision based on oncological results.Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy.PCA3 urinary test versus 1H-MRSI and DCEMR in the detection of prostate cancer foci in patients with biochemical alterations.A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer.Comparison between ultrasound-guided and digital-guided anesthesia before prostatic biopsy.Prostate cancer gene 3 and multiparametric magnetic resonance can reduce unnecessary biopsies: decision curve analysis to evaluate predictive models.Pathology of BPH.Plant extracts in BPH.High Frequency of JCV DNA Detection in Prostate Cancer Tissues.The role of hormonal therapy in the treatment of prostatic carcinoma.Is medical therapy an expensive way for delaying surgery in BPH patients?Is there always a role for radical prostatectomy in the treatment of localized prostate cancer?Results, questions, perspectives of a study on human Polyomavirus BK and molecular actors in prostate cancer development.
P50
Q26741277-D0FB2A29-0301-4913-9710-C19C88C70B79Q28073742-1BC8F8EB-4566-4B2F-B451-9A3D043173F8Q33404776-9D386B8B-6C74-4B9C-A55F-9A34E73DC9F0Q33478538-1788BBE5-3C8E-4F21-BC7C-D6A762D65F8CQ34448137-635D2101-5364-4446-9CF8-412995EF3167Q34572990-E6F20D90-D0D9-4A85-B1FB-62443CEB6F55Q34633830-7F67F1B0-A4B3-4FFC-B3DD-575EB7123902Q34694731-4C56975C-312E-46C4-90DC-56561F21ACAFQ35005465-5743EE5C-F74D-43BF-A8C6-10C828946BE9Q35072155-28DF8706-9B8D-49F9-932E-E8AD1C7EFB7BQ35667167-E0579A83-1ADE-41D2-9B65-701FE6F98913Q35906156-46C0CF9A-F242-4C8C-8BAC-BA9631788B67Q35947110-FC713C92-F14D-4086-A121-FB0F96B95B10Q36451552-B9208F78-6515-4EA6-AF53-E44CE814A049Q36754671-91D3F3EB-99DC-4544-A267-DCD94E71E182Q36873305-7466C267-D570-4117-8B75-00686C850DABQ36970886-5EEC96C5-A97C-4C93-B8A1-EF4103CCEF34Q37161343-2DCB52A0-19A1-46F5-8687-469FC2031450Q37592807-6897A7BE-BD63-4BE8-B86F-DB8A3BD233F9Q37761845-EC481686-7E52-417A-97FF-146A6CBC6C95Q37792135-5DAD0710-0652-429F-A9F2-C0B7A9882A3CQ37851219-9AE0175B-72E0-4674-AB20-1CAF34733FD4Q37991832-A02C1254-4EC5-4B75-98CB-0549E681ED3AQ38148454-2B07F037-D75E-4FF3-B7AB-9EA53CC5FA12Q38696841-17D7CE4E-955B-491B-8D23-A088DB638B94Q38892158-7BC9292B-88FF-495C-A4EA-40328B0BF4C0Q39180649-3F607C4D-4AB4-4681-82AC-2DAF06C5B2C2Q39262401-91919D3C-5468-4339-AA17-5B70595AA0C3Q39895770-52DAEA81-1E5A-4207-8053-2BBF80DF6F6EQ39980053-036E16EE-E8D7-4443-B84B-80A97BB51235Q40009107-229BB17C-EEDF-46EF-ABE6-6FDF2DFB65CBQ40093590-A3DBE169-6683-4CAE-94B3-8F77CA503883Q40140668-15B52ED2-C769-440E-94EC-4FA65BDE1FE3Q40390452-71B53052-7A8B-4224-8994-65152BD79C0DQ40390459-4BFA3AE9-8FEF-41EA-8C04-3DC9EBD5C282Q40774673-B5F56C20-4C87-4684-A415-BC00D6382E1CQ40837320-5947E25D-41EF-4885-80F8-A64059C3F530Q40964023-DBC655E7-2F14-4DB7-A4E2-822D0A0E4A87Q41117339-C587308F-CB98-49E3-BBB6-7CDE50B1ECC1Q41225208-70153F9A-572C-4F42-9B4E-516643213A3E
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alessandro Sciarra
@ast
Alessandro Sciarra
@en
Alessandro Sciarra
@es
type
label
Alessandro Sciarra
@ast
Alessandro Sciarra
@en
Alessandro Sciarra
@es
prefLabel
Alessandro Sciarra
@ast
Alessandro Sciarra
@en
Alessandro Sciarra
@es
P106
P1153
14122185100
P21
P31
P496
0000-0002-7899-8056